Results 91 to 100 of about 166,355 (310)

Characterization of a Cisplatin-resistant HeLa subline and mechanisms of cisplatin-resistance.

Journal of Japan Society for Oral Tumors, 1990
ヒト口腔領域由来腫瘍細胞, UEDA, NAKATA, KANETSUKI, HSG, HSY, 子宮頸部由来HeLa, 外陰部由来A431の7種の培養細胞を用いてシスプラチンに対する感受性を検索した。腺癌細胞は扁平上皮癌細胞に比べてシスプラチンに対して高い感受性を示し, 唾液腺腺癌に化学療法が有用であると示唆された。また, 一方扁平上皮癌細胞は自然耐性を示した。シスプラチンに感受性の高い細胞は高い細胞内シスプラチン濃度を示し, シスプラチンの取り込みは殺細胞効果を反映すると考えられた。シスプラチン耐性のメカニズムを解明するためにHeLa細胞を用いてシスプラチン耐性細胞を分離した (HeLaDDP) 。同細胞はシスプラチン非存在下17ケ月間継代培養した後も約4.3倍の安定した耐性を発現していた ...
Miho Furue, Tetsuji Okamoto, Kazuaki Takada   +2 more
openaire   +2 more sources

Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer

Brazilian Journal of Medical and Biological Research, 2013
Cisplatin resistance remains one of the major obstacles when treating epithelial ovarian cancer. Because oxaliplatin and nedaplatin are effective against cisplatin-resistant ovarian cancer in clinical trials and signal transducer and activator of ...
W.J. Sheng, H. Jiang, D.L. Wu, J.H. Zheng   +3 more
doaj   +1 more source

Reduced Expression of miRNA-27a Modulates Cisplatin Resistance in Bladder Cancer by Targeting the Cystine/Glutamate Exchanger SLC7A11 [PDF]

, 2014
Purpose: Resistance to cisplatin-based chemotherapy is a major obstacle to bladder cancer treatment. We aimed to identify microRNAs (miRNA) that are dysregulated in cisplatin-resistant disease, ascertain how these contribute to a drug-resistant phenotype,
Bertz, S., Bryant, H.E., Catto, J.W.F., Drayton, R.M., Dudziec, E., Hartmann, A., Peter, S.   +6 more
core   +2 more sources

Hippo pathway at the crossroads of stemness and therapeutic resistance in breast cancer

Molecular Oncology, EarlyView.
Dysregulation of the Hippo pathway drives nuclear accumulation of YAP/TAZ, activating stemness‐related transcriptional programs that sustain breast cancer stemness and fuel therapeutic resistance across subtypes, underscoring Hippo signaling as a targetable vulnerability. Figure created and edited with BioRender.com.
Giulia Schiavoni, Antonella Palmese, Stefano Scalera, Laura Cipriani, Davide Mascolo, Patrizia Vici, Teresa Arcuri, Lorena Filomeno, Eriseld Krasniqi, Giovanni Blandino, Giulia Bon, Marcello Maugeri‐Saccà   +11 more
wiley   +1 more source

A strategy to combine pathway-targeted low toxicity drugs in ovarian cancer. [PDF]

, 2015
Serous Ovarian Cancers (SOC) are frequently resistant to programmed cell death. However, here we describe that these programmed death-resistant cells are nonetheless sensitive to agents that modulate autophagy.
Bartakova, Alena, Davis, Mitzie-Ann, Delaney, Joe R, Haft, Carley, Lu, Dan, McCabe, Katelyn E, Patel, Chandni, Schlaepfer, David D, Stupack, Dwayne G, Tancioni, Isabelle, von Schalscha, Tami   +10 more
core   +2 more sources

CD47 promotes mitogen‐activated protein kinase and epithelial‐to‐mesenchymal transition molecular programs to drive prometastatic phenotypes in non‐small cell lung cancer

Molecular Oncology, EarlyView.
Beyond its role in immune evasion, this study identified that CD47 drives tumor‐intrinsic signaling in non‐small cell lung cancer (NSCLC). Transcriptomic profiling and functional studies revealed that CD47 regulates cell adhesion, migration, and metastasis through an ERK–EMT signaling axis.
Asa P.Y. Lau, Lilian G. Zhai, Ryunosuke Hoshi, Zackary Rousseau, Abraam Zakhary, Yin Fang Wu, Rola M. Saleeb, Heyu Ni, Kelsie L. Thu   +8 more
wiley   +1 more source

Autophagy and extracellular vesicles mediate cisplatin resistance in oral squamous cell carcinoma with LC3B-II as a potential non-invasive biomarker

Scientific Reports
Drug resistance remains a critical challenge in cancer chemotherapy, particularly in oral squamous cell carcinoma (OSCC). Recent findings have highlighted the significant roles that autophagy and extracellular vesicles (EVs) play in contributing to ...
Kar-Yan Su, Xin-Hui Khoo, Ian C. Paterson, Bey-Hing Goh, Wai-Leng Lee   +4 more
doaj   +1 more source

LTBP2 regulates cisplatin resistance in GC cells via activation of the NF-κB2/BCL3 pathway

Genetics and Molecular Biology
Gastric cancer (GC) often develops resistance to cisplatin treatment, but while latent transforming growth factor β-binding protein (LTBP2) is recognized as a potential regulator in GC, its specific role in cisplatin resistance is not fully understood ...
Jun Wang, Wenjia Liang, Xiangwen Wang, Zhao Chen, Lei Jiang   +4 more
doaj   +1 more source

Patient derived xenograft models of small-cell lung cancer provide molecular insights into mechanisms of chemotherapy cross-resistance [PDF]

, 2018
Small Cell Lung Cancer (SCLC) is a highly aggressive neuroendocrine tumor with a 5% survival rate over 5 years. Though SCLC comprises 13% of all cases of lung cancer the median survival time of 14.5 months has seen little improvement over the last four ...
Myers, David Thomas
core  

Expression signatures of cisplatin- and trametinib-treated early-stage medaka melanomas [PDF]

, 2019
Small aquarium fish models provide useful systems not only for a better understanding of the molecular basis of many human diseases, but also for first-line screening to identify new drug candidates.
Boswell, William, Klotz, Barbara, Kneitz, Susanne, Lu, Yuan, Postlethwait, John, Shartl, Manfred, Walter, Ronald B, Warren, Wesley   +7 more
core   +2 more sources